Beyond the blood-brain barrier: amivantamab plus lazertinib in EGFR-mutant non-small cell lung cancer with brain and leptomeningeal metastases.
- DOI
- 10.21037/tlcr-2026-1009
- Published
- 2026 Oct 30
- Container
- Translational lung cancer research
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.21037/tlcr-2026-1009,
title = {Beyond the blood-brain barrier: amivantamab plus lazertinib in EGFR-mutant non-small cell lung cancer with brain and leptomeningeal metastases.},
author = {Pan K and Sun SY},
year = {2026},
journal = {Translational lung cancer research},
doi = {10.21037/tlcr-2026-1009},
url = {https://doi.org/10.21037/tlcr-2026-1009}
}RIS
TY - JOUR TI - Beyond the blood-brain barrier: amivantamab plus lazertinib in EGFR-mutant non-small cell lung cancer with brain and leptomeningeal metastases. AU - Pan K AU - Sun SY PY - 2026 JO - Translational lung cancer research DO - 10.21037/tlcr-2026-1009 UR - https://doi.org/10.21037/tlcr-2026-1009 ER -
APA
K, P., & SY, S. (2026). Beyond the blood-brain barrier: amivantamab plus lazertinib in EGFR-mutant non-small cell lung cancer with brain and leptomeningeal metastases.. Translational lung cancer research. https://doi.org/10.21037/tlcr-2026-1009
Source records
- pubmed · retrieved 2026-11-10T12:32:23.651Z